Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03819517 · ClinicalTrials.gov registry record · Early Phase 1
Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease
A Early Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT03819517 is a Early Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 26 participants.
The verdict
NCT03819517, a Early Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Researchers have found a link between chronic obstructive pulmonary disease (COPD) and heart disease; however, a link is all they have found. Cardiovascular health in COPD is controlled by different mechanisms including vascular health and systemic inflammation. The investigators have collected preliminary data to support that concentrations of Sirtuin 1 (Sirt1), a protein that plays a key role in cardioprotection, may be involved in cardiovascular health in patients with COPD. Resveratrol, an over the counter natural polyphenol found in a variety of food, is a direct activator of Sirt1 and has been used to improve cardiovascular health in different cohorts. The current project is an attempt to expand previous findings and explore the effects of the sub-chronic use of resveratrol in sustaining the improvements in cardiovascular health in COPD.
Interventions
- OTHER Placebo
- DRUG Resveratrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2023-08-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03819517
The ClinicalTrials.gov registry entry for NCT03819517 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03819517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03819517 about?
NCT03819517 is a clinical study titled "Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease". Researchers have found a link between chronic obstructive pulmonary disease (COPD) and heart disease; however, a link is all they have found. Cardiovascular health in COPD is controlled by different mechanisms including vascular health and systemic inflammation. The investigators have collected prel...
What is the current status of trial NCT03819517?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2019-07-01. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT03819517?
The interventions under investigation include: Placebo (OTHER), Resveratrol (DRUG).
Who is sponsoring clinical trial NCT03819517?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.